Infection Control
Methodology & AI Transparency ⓘ
Infection Control Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Every year, lives are lost because of the spread of infections in hospitals.
- 2 Real-world patient consensus: Mapped to Bacterial, Viral & Fungal Infections under ICD-10-CM B37.4 for Infection Control clinical workups.
- 3 Typical cash cost range: Differential triage of Infection Control (B37.4) utilizes antimicrobial stewardship (narrow-spectrum in Infection Control (B37.4: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Key Infections & Antivirals biomarkers for Infection Control (B37.4): Complete Blood Count in Infection Control (B37.4: (WBC & Differential)) & C-Reactive Protein / in Infection Control (B37.4: Procalcitonin) (Resolution to baseline (B37.4)).
Ask our AI Specialists anything about Infection Control
What Is Infection Control?
Every year, lives are lost because of the spread of infections in hospitals. Health care workers can take steps to prevent the spread of infectious diseases . These steps are part of infection control. Proper hand washing is the most effective way to prevent the spread of infections in hospitals. If you are a patient, don't be afraid to remind friends, family and health care providers to wash their hands before getting close to you.
Pathophysiology, Underlying Causes & Clinical Presentation
Infection Control (B37.4) alters infections & antivirals homeostasis through cytokine pyrogen release [Infection Control B37.4]; Cross-referenced with NIH MeSH (Infection Control), clinical remission targets C-Reactive Protein / in Infection Control (B37.4: Procalcitonin) within Resolution to baseline (B37.4).
Common Symptoms & Clinical Signs
- • Covering coughs and sneezes
- • Staying up to date with vaccinations
- • Presentation of Infection Control (B37.4): painful vesicular rash in Infection Control (B37.4: in a dermatomal)
- • Secondary Infection Control clinical sign: regional lymph node in Infection Control (B37.4: tenderness or acute)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Infection Control Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B37.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Infection Control (B37.4: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B37.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Infection Control (B37.4: Procalcitonin) | Resolution to baseline (B37.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Infection Control (B37.4: Culture & Sensitivity) | Pathogen clearance / negative test (B37.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Infection Control
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Microgestin 1/20 (Norethindrone Acetate/Ethinyl Estradiol) Microgestin 1/20 • RxCUI 1989873-B51862868 | Birth Control Agent | 84% | $0.1652 | $ 20.40 /mo |
| Cefadroxil Duricef • RxCUI 309049 | Cephalosporin Antibacterial | 83% | $0.1964 | $ 10.51 /mo |
| Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Generic • RxCUI 643066 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor | 86% | $1.1078 | $ 53.37 /mo |
| Lopinavir and Ritonavir Kaletra • RxCUI 311369 | Protease Inhibitor | 92% | $5.2003 | $ 185.00 /mo |
| Phenoxybenzamine Hydrochloride Dibenzyline • RxCUI 861402 | alpha-Adrenergic Blocker | 74% | $0.7800 | $ 1011.21 /mo |
| Tenofovir Disoproxil Fumarate Viread • RxCUI 349251 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 84% | $0.2938 | $ 10.80 /mo |
| Emtricitabine and Tenofovir Disoproxil Fumarate Truvada • RxCUI 476556 | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 93% | $59.5926 | $ 185.00 /mo |
| Histamine Histamine Generic • RxCUI RXN-650449998-1760 | FDA Prescription Therapeutic Agent | 83% | $1.8800 | $ 84.64 /mo |
| Primidone Mysoline • RxCUI 96304 | Anti-epileptic Agent | 87% | $0.0914 | $ 6.19 /mo |
| Insulin Lispro Humalog, Humalog Mix50/50 Kwikpen • RxCUI 242120 | Insulin Analog | 80% | $8.1491 | $ 185.00 /mo |
| Tydemy (Drospirenone, Ethinyl Estradiol and Levomefolate Calcium and Levomefolate Calcium) Tydemy • RxCUI 1050493-B68180904 | Birth Control Agent | 87% | $2.9093 | $ 64.18 /mo |
| Sronyx (Levonorgestrel and Ethinyl Estradiol) Sronyx • RxCUI 748868 | Birth Control Agent | 84% | $0.1734 | $ 20.99 /mo |
| Atazanavir Reyataz • RxCUI 402245 | Protease Inhibitor | 92% | $1.0536 | $ 26.11 /mo |
| Sodium Sulfacetamide 8% Sulfur 4% Sodium Sulfacetamide, Sulfur • RxCUI 1010234 | Sulfonamide Antibacterial | 89% | $1.9213 | $ 86.31 /mo |
| Glydo- Lidocaine Hydrochloride Jelly Glydo- Lidocaine Hydrochloride Jelly Generic • RxCUI 1011852 | Amide Local Anesthetic | 86% | $0.5046 | $ 28.94 /mo |
| Yaz (Drospirenone and Ethinyl Estradiol) Yaz • RxCUI 1099026-B50419405 | Birth Control Agent | 79% | $5.8438 | $ 7.36 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Infection Control)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Urinary tract infections in patients with diabetes treated with: What a 3,152-Participant Study Found Treatment of type 2 diabetes with once-daily dapagliflozin 5 or 10mg is accompanied by a slightly increased risk of urinary tract infection. Journal of diabetes and its complications • 2013-01-15 • Meta-Analysis | N = 3,152 | 99/100 | PMID 23849632 ↗ |
| New Insights on Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children: What a 3,765-Participant Study Found The variability in VE algorithms indicates challenges in accurately assessing VE against asymptomatic infections. The Journal of infectious diseases • 2025-07-11 • Phase III Randomized Trial | N = 3,765 | 96/100 | PMID 40100744 ↗ |
| New Insights on Sulopenem versus Amoxicillin/Clavulanate for the Treatment of Uncomplicated: What a 2,222-Participant Study Found Sulopenem was noninferior to amoxicillin/clavulanate for the treatment of adult women with uncomplicated urinary tract infection, but was associated with more frequent mild side effects. NEJM evidence • 2025-07-15 • Phase III Randomized Trial | N = 2,222 | 96/100 | PMID 40552968 ↗ |
| New Insights on Long-term protection from naturally acquired immunity against hepatitis E virus: What a 3,194-Participant Study Found Six were hospitalized, all of whom were baseline seronegative. Nature communications • 2025-12-17 • Phase III Randomized Trial | N = 3,194 | 96/100 | PMID 41407683 ↗ |
| New Insights on Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the: What a 1,046-Participant Study Found Both vonoprazan-based regimens were superior to proton pump inhibitor-based triple therapy in clarithromycin-resistant strains and in the overall study population. Gastroenterology • 2022-09-15 • Phase III Randomized Trial | N = 1,046 | 96/100 | PMID 35679950 ↗ |
Infection Control Patient Community & “People Like Me” Threads
Filter Infection Control community threads and patient logs by age, biological sex, dosage, and treatment duration.